These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24853673)

  • 1. Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders.
    Linnerbauer S; Behrends U; Adhikary D; Witter K; Bornkamm GW; Mautner J
    PLoS Pathog; 2014 May; 10(5):e1004068. PubMed ID: 24853673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.
    Adhikary D; Behrends U; Boerschmann H; Pfünder A; Burdach S; Moosmann A; Witter K; Bornkamm GW; Mautner J
    PLoS One; 2007 Jul; 2(7):e583. PubMed ID: 17611619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
    Mautner J; Bornkamm GW
    Eur J Cell Biol; 2012 Jan; 91(1):31-5. PubMed ID: 21458882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
    Sebelin-Wulf K; Nguyen TD; Oertel S; Papp-Vary M; Trappe RU; Schulzki A; Pezzutto A; Riess H; Subklewe M
    Transpl Immunol; 2007 Apr; 17(3):203-10. PubMed ID: 17331848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo.
    Johannessen I; Bieleski L; Urquhart G; Watson SL; Wingate P; Haque T; Crawford DH
    J Med Virol; 2011 Sep; 83(9):1585-96. PubMed ID: 21739450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
    Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes.
    Bräuninger A; Spieker T; Mottok A; Baur AS; Küppers R; Hansmann ML
    Eur J Immunol; 2003 Jun; 33(6):1593-602. PubMed ID: 12778477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles.
    Adhikary D; Behrends U; Feederle R; Delecluse HJ; Mautner J
    J Virol; 2008 Apr; 82(8):3903-11. PubMed ID: 18272580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
    Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
    J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.
    Ning RJ; Xu XQ; Chan KH; Chiang AK
    Immunology; 2011 Oct; 134(2):161-71. PubMed ID: 21896011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice.
    Wagar EJ; Cromwell MA; Shultz LD; Woda BA; Sullivan JL; Hesselton RM; Greiner DL
    J Immunol; 2000 Jul; 165(1):518-27. PubMed ID: 10861091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-uniform
    Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
    Front Immunol; 2019; 10():2489. PubMed ID: 31736946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
    Dolcetti R
    Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
    Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
    Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
    Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation.
    Cooper RS; Sutherland C; Smith LM; Cowan G; Barnett M; Mitchell D; McLean C; Imlach S; Hayes A; Zahra S; Manchanayake C; Vickers MA; Graham G; McGowan NWA; Turner ML; Campbell JDM; Fraser AR
    Front Immunol; 2024; 15():1412211. PubMed ID: 39011042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic variations in EBNA3C of EBV associate with posttransplant lymphoproliferative disorder.
    Maloney EM; Busque VA; Hui ST; Toh J; Fernandez-Vina M; Krams SM; Esquivel CO; Martinez OM
    JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32213705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells.
    Long HM; Zuo J; Leese AM; Gudgeon NH; Jia H; Taylor GS; Rickinson AB
    Blood; 2009 Jul; 114(4):807-15. PubMed ID: 19443664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.